24 results
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Penicillium marneffei Infections ... Treating Acute Infection ... itraconazolea 200 mg PO BID ... Prevention #Treatment #management ... #HIVAIDS #pharmacology
Important causes of diarrhea in people with HIV/AIDS
Severity, chronicity/persistence will depend On CD4 count & sites
will depend On CD4 ... count & sites of infection ... insufficiency, drug-induced ... Washington University ID ... #Diarrhea #HIVAIDS
IDSA Recommendations for Treating Isospora belli Infection in HIV-AIDS
Treating Isospora belli Infection
General Management Considerations:
 • Fluid
General Management ... Patients with CD4 ... Sustained increase in CD4 ... Prevention #Treatment #management ... #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
Bacterial Enteric Infections ... (CDI): • Vancomycin ... Prevention #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
Myasthenic Crisis Checklist - Myasthenia Gravis

Evaluation 
 - Chest X-ray and lung ultrasound (exclude other lung
Myasthenic Crisis Checklist ... possible - Infectious ... if symptoms of infection ... Drugs to avoid ( ... #Management #CriticalCare
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
ART to maintain CD4 ... intraocular levels of drug ... Valganciclovir 900 mg PO BID ... Prevention #Treatment #management ... #HIVAIDS #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
leishmaniasis and CD4 ... Prevention #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
suspension 400 mg PO BID ... Prevention #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
Clarithromycin 500 mg PO BID ... necessary based on drug-drug ... Prevention #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA Recommendations for Treating Herpes Simplex Virus (HSV) Infections in HIV-AIDS
Treating Orolabial Lesions (Duration: 5–10 days)
Simplex Virus (HSV) Infections ... Mucocutaneous HSV Infections ... Prevention #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology